TrialAutopsyBuilt by Jawad Momani (Pwnedl0l)

Autopsy report · NCT04579523

²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma

Cause of deathSlow enrollment Automatic label, confidence 0.9, unverified. How labels are made.
“Study withdrawn before opening to accrual.”

The sponsor’s own words in the registry.

Life of this trial

202020212022202320242025202620272028Registered2020-09-23Withdrawn (as of)2026-09-11Planned start2027-06-01 (planned)

Vital statistics

Status
Withdrawn
Phase
Phase 1
Sponsor
Fred Hutchinson Cancer Center
Sponsor type
University, hospital or other
Conditions
Multiple Myeloma; Recurrent Multiple Myeloma; Refractory Multiple Myeloma
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation; Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10; Cyclophosphamide; Fludarabine Phosphate; Total-Body Irradiation; Biospecimen Collection
Participants
0
Sites
1
Countries
United States

Trials that died the same way

Look deeper

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.